(Q40716128)

23 September 2017

In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia (English)

1 reference

23 September 2017

0 references

1 reference

4

1 reference

23 September 2017

Paul La Rosée

1

0 references

Michael O'Dwyer

object named as

Michael E O'Dwyer

series ordinal

3

0 references

author name string

Kara Johnson

series ordinal

2

1 reference

PubMed ID

12135670

23 September 2017

language of work or name

1 reference

1 July 2002

1 reference

23 September 2017

Experimental Hematology

1 reference

23 September 2017

30

1 reference

23 September 2017

729-737

1 reference

23 September 2017

7

1 reference

The biology of chronic myeloid leukemia

23 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Role of modelling in joint action studies

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

Arginine butyrate downregulates p210 bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2802%2900836-6

7 January 2021

10.1016/S0301-472X(02)00836-6

Identifiers

DOI

1 reference

23 September 2017

1 reference

PubMed ID

12135670